Login
Companies $PTGX
$124.83 +$0.00 (0.0%) After hours
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc

protagonist-inc.com

What Do They Do?

Develops peptide-based drug candidates for inflammatory diseases, blood disorders and obesity, and licenses some candidates to pharmaceutical partners.

How Do They Make Money?

Pharmaceutical partners pay upfront and milestone amounts and share costs under collaboration agreements; Protagonist also earns royalties on licensed products’ sales. License income is earned when a partner can use the rights, while royalties follow product sales.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical partners JNJ and Takeda contract with Protagonist under license and collaboration agreements; revenue includes their upfront and milestone payments and cost-sharing payments.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2023: 100% from one customer

Do Revenues Turn Into Profits?

Not on paper. It lost $130.1M in FY2025, but brought in more cash than it spent: $56.1M of free cash flow.

Operating income, FY2025
−344% of revenue
▼ Turned to a loss vs FY2024 ($252.8M, 58%)
Net income, FY2025
−283% of revenue
▼ Turned to a loss vs FY2024 ($275.2M, 63%)
Free cash flow, FY2025
122% of revenue
▼ −69% vs FY2024 ($182.8M, 42%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +5724%
vs $4.7M in Q3 FY2025
Net income
▲ Turned profitable
vs −$39.3M in Q3 FY2025
  • Aug 5, 2026 ICOTYDE gained U.S. approval as Takeda took worldwide rusfertide rights ICOTYDE’s approval triggered a milestone payment; Takeda holds worldwide rusfertide rights, with further milestones and royalties payable to Protagonist.

Growing. Revenue grew 68% in 4 years, from $27.4M in FY2021 to $46M in FY2025, about 14% a year.

Broader disease focus The older report describes hematology and inflammatory programs; the latest also describes obesity candidates, including peptide agonists in oral and injectable forms.

Rusfertide partnership The older report describes rusfertide as wholly owned; the latest describes a co-development and co-commercialization arrangement with Takeda.

Who Do They Compete With?

Competes with Novartis, Eli Lilly, Bausch Health, Johnson & Johnson, AbbVie, UCB, Amgen, Pfizer, Bristol Myers Squibb, Takeda, Alumis, Gilead, Incyte, Italfarmaco, Silence Therapeutics, Disc Medicine, Novo Nordisk, Viking Therapeutics, Structure Therapeutics, and Boehringer Ingelheim

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support